search button

Efficacy and tolerability of once‑daily 160 mg valsartan in Chinese patients with mild to moderate hypertension

  • Authors:
    • Ningling Sun
    • Yingqing Feng
    • Pingjin Gao
    • Xiaoping Chen
    • Litong Qi
    • Shuyang Zhang
    • Yugang Dong
    • Xinchun Yang
    • Xinli Li
    • Yundai Chen
    • Lingli Liu

  • View Affiliations

  • Published online on: January 17, 2017     https://doi.org/10.3892/etm.2017.4051
  • Pages: 1109-1116
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present multicentre, prospective, open‑label, single treatment arm study (Val‑Perfect) examined the efficacy and tolerability of once‑daily valsartan monotherapy (80 mg for two weeks, followed by 160 mg for eight weeks) in 195 Chinese patients with mild to moderate hypertension, using office, home, and ambulatory blood pressure (BP) monitoring. Significant mean reductions (P<0.0001) were observed in office BP from baseline to week 10, with mean sitting systolic BP (MSSBP) and mean sitting diastolic BP (MSDBP) values of 15.6±12.3 and 11.1±8.6 mmHg, respectively. The office BP control rate at week 10 was 56.9% (target MSSBP/MSDBP <130/80 mmHg for patients with type 2 diabetes or chronic kidney disease, <140/90 mmHg for others). Valsartan treatment significantly reduced mean 24‑h SBP/DBP (‑6.1/‑4.4 mmHg; both P<0.0001) and mean home‑monitored SBP/DBP (‑13.3/‑9.1 mmHg; both P<0.0001) at week 10. The incidence of adverse events (AEs) leading to discontinuation (1.5%) or drug‑related AEs (3.1%) was low, with no instances of mortality or drug‑related serious AEs. These results indicate that 160 mg valsartan is safe and effective at lowering BP in Chinese patients with mild to moderate hypertension. The significant reductions in office‑based and out‑of‑office BP measures support the clinical relevance of moderate‑dose valsartan monotherapy for effective 24‑h BP control.
View Figures
View References

Related Articles

Journal Cover

March-2017
Volume 13 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.7
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Sun N, Feng Y, Gao P, Chen X, Qi L, Zhang S, Dong Y, Yang X, Li X, Chen Y, Chen Y, et al: Efficacy and tolerability of once‑daily 160 mg valsartan in Chinese patients with mild to moderate hypertension. Exp Ther Med 13: 1109-1116, 2017
APA
Sun, N., Feng, Y., Gao, P., Chen, X., Qi, L., Zhang, S. ... Liu, L. (2017). Efficacy and tolerability of once‑daily 160 mg valsartan in Chinese patients with mild to moderate hypertension. Experimental and Therapeutic Medicine, 13, 1109-1116. https://doi.org/10.3892/etm.2017.4051
MLA
Sun, N., Feng, Y., Gao, P., Chen, X., Qi, L., Zhang, S., Dong, Y., Yang, X., Li, X., Chen, Y., Liu, L."Efficacy and tolerability of once‑daily 160 mg valsartan in Chinese patients with mild to moderate hypertension". Experimental and Therapeutic Medicine 13.3 (2017): 1109-1116.
Chicago
Sun, N., Feng, Y., Gao, P., Chen, X., Qi, L., Zhang, S., Dong, Y., Yang, X., Li, X., Chen, Y., Liu, L."Efficacy and tolerability of once‑daily 160 mg valsartan in Chinese patients with mild to moderate hypertension". Experimental and Therapeutic Medicine 13, no. 3 (2017): 1109-1116. https://doi.org/10.3892/etm.2017.4051